Safety, Tolerability and Efficacy for CGF166 in Patients With Unilateral or Bilateral Severe-to-profound Hearing Loss

NCT02132130 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

22

Enrollment

INDUSTRY

Sponsor class

Conditions

Unilateral Severe to Profound Hearing Loss OR Bilateral Severe to Profound Hearing Loss

Interventions

DRUG: CGF166

Sponsor

Novartis Pharmaceuticals